Examinando por Autor "Santos Lasaosa, Sonia"

Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Diagnóstico y tratamiento de los trastornos de la presión intracraneal: documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología
    (Spanish Society of Neurology, 2025-01) García Ull, Francisco José; González García, Nuria; Torres Ferrús, Marta; García Azorín, David; Molina Martínez, Francisco José; Beltrán Blasco, Isabel; Santos Lasaosa, Sonia; Latorre, Germán; Gago Veiga, Ana Beatriz; Láinez, José Miguel; Porta Etessam, Jesús; Nieves Castellanos, Candela; Mínguez Olaondo, Ane; López Bravo, Alba; Quintas, Sonia; Morollón, Noemí; Díaz Insa, Samuel; Belvís Nieto, Roberto; Irimia, Pablo
    Los trastornos primarios de la presión intracraneal incluyen la hipertensión intracraneal idiopática y la hipotensión intracraneal espontánea. El diagnóstico y tratamiento de ambas entidades ha presentado un avance destacable en los últimos años, por lo que desde el Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología consideramos necesaria la elaboración de este documento de consenso con la inclusión de algoritmos diagnósticos y terapéuticos para mejorar su manejo en la práctica diaria. Este documento ha sido redactado por un comité de expertos del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología tras realizar una revisión sistemática de la bibliografía, incorporando la experiencia de los participantes y estableciendo unas recomendaciones prácticas con niveles de evidencia y grados de recomendación.
  • Miniatura
    Ítem
    Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
    (BioMed Central Ltd, 2023-06-02) Muñoz-Vendrell, Albert; Campoy, Sergio; Caronna, Edoardo; Alpuente Ruiz, Alicia; Torres Ferrús, Marta; Nieves Castellanos, Candela ; Olivier, M.; Campdelacreu Fumadó, Jaume; Prat, Joan; Camiña Muñiz, J.; Molina Martínez, Francisco José ; Mínguez Olaondo, Ane; Ruibal, M.; Santos Lasaosa, Sonia; Navarro Pérez, María Pilar; Morollón, Noemí ; López Bravo, Alba ; Cano Sánchez, L.M.; García-Sánchez, S.M.; García-Ull, Jesica; Rubio-Flores, Laura.; Gonzalez Martinez, Alicia; Quintas, Sonia ; Echavarría Íñiguez, Ana ; Gil Luque, Sendoa; Castro-Sánchez, M.V.; Adell Ortega, V.; García Alhama, J.; Berrocal-Izquierdo, N.; Belvís Nieto, Roberto; Díaz Insa, Samuel ; Pozo Rosich, Patricia ; Huerta Villanueva, Mariano
    Background: Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods: In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results: A total of 162 patients were included, median age 68 years (range 65–87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.1 ± 7.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days ≥ 30%, ≥ 50%, ≥ 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions: Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice. Graphical Abstract: [Figure not available: see fulltext.]